Phase II Trial of Erlotinib, a Small Molecule Tyrosine Kinase Inhibitor of EGFR, Prior to Surgery or Radiation in Patients With Aggressive Squamous Cell Cancers (SCC) of the Skin.
Phase of Trial: Phase II
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Erlotinib (Primary)
- Indications Skin cancer
- Focus Therapeutic Use
- 25 May 2016 Status changed from completed to discontinued.
- 03 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Mar 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Mar 2018 as reported by ClinicalTrials.gov.